News articles about AxoGen (NASDAQ:AXGN) have been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AxoGen earned a news impact score of 0.04 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 47.125167897127 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Here’s What to Focus on: AxoGen Inc (NASDAQ: AXGN) – Alpha Beta Stock (alphabetastock.com)
- AxoGen, Inc. Announces Proposed Public Offering of Common Stock – GlobeNewswire (press release) (globenewswire.com)
- AxoGen, Inc. Announces Pricing of Public Offering of Common Stock – GlobeNewswire (press release) (globenewswire.com)
- AxoGen (AXGN) Prices Public Offering of Common Stock at $21/Share (streetinsider.com)
- AxoGen (AXGN) Announces 1M Share Common Offering (streetinsider.com)
Shares of AxoGen (NASDAQ AXGN) traded up $1.00 during trading on Friday, hitting $23.60. The stock had a trading volume of 570,475 shares, compared to its average volume of 290,008. AxoGen has a 12-month low of $8.05 and a 12-month high of $25.15. The company has a debt-to-equity ratio of 1.93, a current ratio of 3.55 and a quick ratio of 2.95.
A number of research firms recently weighed in on AXGN. BidaskClub downgraded AxoGen from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Leerink Swann initiated coverage on AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price objective on shares of AxoGen in a research note on Monday, August 21st. Finally, Roth Capital reissued a “buy” rating and issued a $21.00 price objective (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AxoGen currently has an average rating of “Buy” and a consensus price target of $18.00.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/11/18/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-axogen-axgn-stock-price.html.
In other news, Director Robert James Rudelius sold 16,143 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $18.00, for a total value of $290,574.00. Following the completion of the transaction, the director now directly owns 43,273 shares of the company’s stock, valued at $778,914. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 9.33% of the company’s stock.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.